drugset / Trial / NCT01132768
The Confirmatory Olmesartan Plaque Regression Study
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Effect of olmesartan medoxomil (20-40 mg) on plaque regression in hypertensive patients with carotid atherosclerosis.
Timeline
- Start
- 2010-05
- Primary completion
- 2011-06
- Completion
- 2011-06
Outcome
Outcome not reported
Stopped (Enrollment): “Low recruitment”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Atenolol | Other / unclassified | 50 mg | Oral |
| Comparator | Atenolol | Other / unclassified | 100 mg | Oral |
| Subject | Olmesartan medoxomil | Unknown | 20 mg | Oral |
| Subject | Olmesartan medoxomil | Unknown | 40 mg | Oral |